DPH-001

N/A

Report date: 2025/03/04 09:31:41

First In Class

Base Information

Drug NameDPH-001

Drug Alias NameAmorphous Formulation of Sorafenib in Mesoporous Magnesium CarbonateDPH001DPH-001

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsSerine/threonine-protein kinase B-raf inhibitorsVascular endothelial growth factor receptor 1 antagonists +[9]

TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[9]

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDisruptive Pharma AB

China Registration ClassN/A

Develop Information

Active CompaniesDisruptive Pharma AB

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A